Hypericin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Hypericin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Hypericin can convert its Small molecule drug profile and HSP x RdRp x SARS-CoV-2 3CLpro biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Hypericin (query alias: Hypericin) |
|---|---|
| Modality / target | Small molecule drug; HSP x RdRp x SARS-CoV-2 3CLpro; HSP inhibitors, RdRp inhibitors, SARS-CoV-2 3CLpro inhibitors |
| Highest global status | NDA/BLA |
| Originator | Soligenix, Inc. |
| Active developers | Soligenix, Inc., Henan Medical University, Fundação Oswaldo Cruz |
The MCP disease footprint includes Cutaneous T-Cell Lymphoma, Plaque psoriasis, Psoriasis vulgaris. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06470451 | Phase 3 | Terminated | 70 | Number of Participants with a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score |
| NCT05442190 | Phase 2 | Completed | 15 | Number of patients that achieve a 0 or 1 score using the 5-point Investigator's Global Assessment scale |
| NCT06149247 | Phase 2 | Completed | 10 | Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL
Phase 2; n=10; evaluation: Positive. Reported fields: ORR = 20.0 % ; ORR = 60.0 %
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis (1)
Phase 2; n=14; evaluation: Positive. Reported fields: PASI = Cohort 1: The majority of patients recording an improvement in the PASI score. Cohort 2: 2/4 evaluable patients achieved an average reduction of approximately 50% in the PASI score. Cohort 3: All three evaluable patients improved in multiple indices, including PASI. % ; PASI = Cohort 1: The majority of patients recording an improvement in the PASI score. Cohort 2: 2/4 evaluable patients achieved an average reduction of approximately 50% in the PASI score. Cohort 3: All three evaluable patients improved in multiple indices, including PASI. % ; PASI = Cohort 1: The majority of patients recording an improvement in the PASI score. Cohort 2: 2/4 evaluable patients achieved an average reduction of approximately 50% in the PASI score. Cohort 3: All three evaluable patients improved in multiple indices, including PASI. %
Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Phase 2; n=10; evaluation: not stated. Reported fields: -; Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score = 1 Participants ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Hypericin addresses Cutaneous T-Cell Lymphoma, Plaque psoriasis, Psoriasis vulgaris. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HSP x RdRp x SARS-CoV-2 3CLpro records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| No matched asset transaction returned. | |||
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
